NCT00630695View on ClinicalTrials.gov

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

December 31, 2011

Conditions
Lymphocele
Interventions
DRUG

Lanreotide LP 90

Lanreotide LP 90

DRUG

Placebo lanreotide

Placebo

Trial Locations (1)

87042

Hôpital Mère Enfant- CHU de Limoges, Limoges

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

University Hospital, Limoges

OTHER

NCT00630695 - Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer | Biotech Hunter | Biotech Hunter